<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543175</url>
  </required_header>
  <id_info>
    <org_study_id>DI/13/111/04/0249</org_study_id>
    <nct_id>NCT04543175</nct_id>
  </id_info>
  <brief_title>Taste Disorders and Their Relation to BMI, FFQ, and EORTC QLQ-BR23 in Breast Cancer Patients During Chemotherapy.</brief_title>
  <official_title>Taste Disorders and Their Relation to Body Mass Index, Food Frequency Questionnaire and Quality of Life in Breast Cancer Patients During Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taste disorders in cancer patients during chemotherapy could be consider as multifactorial&#xD;
      disease, it is related with changes of food consumption. Approximately 36-69% of the patients&#xD;
      under chemotherapy suffer oral toxicity or dysgeusia&#xD;
&#xD;
      A prospective case- only observational study was conducted in patients of the Hospital&#xD;
      General de México for two years. A self-reported taste survey was used, and patients scored&#xD;
      their results in a Likert scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of taste disorders and perception of the four basic flavors</measure>
    <time_frame>21 days</time_frame>
    <description>to assess the prevalence of taste alterations perception of the four basic flavors (sweet, salty, bitter and acidic) in newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">106</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Taste Disorders</condition>
  <condition>Dysgeusia</condition>
  <condition>Ageusia</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Chemotherapy breast cancer patients</arm_group_label>
    <description>Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Taste disorder´s test</intervention_name>
    <description>Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.</description>
    <arm_group_label>Chemotherapy breast cancer patients</arm_group_label>
    <other_name>Taste disorders</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of Oncology ward in Hospital General de Mexico between 20 and 60 years old with&#xD;
        newly diagnosed breast cancer.&#xD;
&#xD;
        and chemotherapy with Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC)&#xD;
        or Docetaxel.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Chemotherapy with Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or&#xD;
        Docetaxel.&#xD;
&#xD;
        Exclusión Criteria:&#xD;
&#xD;
          -  No smokers Infections in oral cavity Acute respiratory diseases Gastro- oesophageal&#xD;
             reflux disease Other types of cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de México</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>Dr. Vanessa Fuchs Tarlovsky</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Taste Disorders</mesh_term>
    <mesh_term>Dysgeusia</mesh_term>
    <mesh_term>Ageusia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

